A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab, Docetaxel|DRUG: Trastuzumab, Docetaxel, Bevacizumab|DRUG: Trastuzumab+Docetaxel+NPLD|DRUG: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Collaborators: Hoffmann-La Roche|Cephalon